Bionano Genomics (BNGO) Debt to Equity (2017 - 2023)

Bionano Genomics has disclosed Debt to Equity across 7 years of filings, most recently posting $0.08 for Q3 2023.

• Debt to Equity for Q3 2023 came in at $0.08, up 154.5% year-over-year; the trailing twelve-month figure through Sep 2023 was $0.08 (up 154.5% YoY), and the FY2022 annual result was $0.04, changed N/A from the prior year.
• Debt to Equity came in at $0.08 for Q3 2023 at Bionano Genomics, up from $0.05 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $5.56 in Q4 2019 to a low of -$14.44 in Q2 2019.
• The 5-year median for Debt to Equity is $0.04 (2021), against an average of -$0.53.
• Peak annual rise in Debt to Equity reached 524.12% in 2019, while the deepest fall reached 552.21% in 2019.
• Bionano Genomics' Debt to Equity stood at $5.56 in 2019, then tumbled by 91.63% to $0.47 in 2020, then tumbled by 91.19% to $0.04 in 2021, then slipped by 8.21% to $0.04 in 2022, then soared by 123.39% to $0.08 in 2023.
• The last three Debt to Equity figures came in at $0.08 (Q3 2023), $0.05 (Q2 2023), and $0.04 (Q1 2023), per Business Quant data.